Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent released polypeptide (GIP) target, is demonstrating promising outcomes in initial patient studies. Ongoing inquiry implies https://optimusbookmarks.com/story21311543/retatrutide-emerging-research-and-potential-clinical-uses